Lifecore Biomedical, Inc.
NASDAQ:LFCRDrug Manufacturers - Specialty & Generic
+$0.02 today
- Market cap
- $242.60M
- Beta
- 1.07
- P/E (TTM)
- -6.1
- EPS (TTM)
- -$0.91
Volume 0.15M
Average 0.29M
LFCR Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
Lifecore Biomedical, Inc.NASDAQ: LFCR
Accounts Receivables · Q3 FY2026 · quarter ended Mar 2026
Accounts receivables of $6.57M in Q3 FY2026
Q3 FY2026 accounts receivables was $6.57M. Trailing-twelve-month accounts receivables was $8.6M. Over 3 fiscal years it compounded at -28.3% a year.
Context
- Accounts receivables amounted to 1.8% of revenue in FY2025, down 0.1 pp from a year earlier.
- Accounts receivables increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly accounts receivables holds near $6.57M or moves back toward the trailing-twelve-month quarterly average of $2.15M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- (2.26M) USD
- Year-over-year change
- +5.4%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-05-25 | (2.26M) | +5.4% |
| FY2024 | 2024-05-26 | (2.39M) | -122.1% |
| FY2023 | 2023-05-28 | 10.82M | +276.3% |
| FY2022 | 2022-05-29 | (6.14M) | -206.3% |
| FY2021 | 2021-05-31 | 5.78M | — |
Accounts Receivables vs competitors
How LFCR compares with its peers on the latest reported figures
- Peers report in different currencies, so accounts receivables is compared through growth and share of revenue rather than absolute size.
- Accounts receivables amounts to 6.4% of revenue for LFCR, versus a peer median of 2.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | CA$23.54M CAD | +624.8% | +60.2% | 7.5% | |
| LTM Mar 2026 | $8.6M USD | — | -28.3% | 6.4% | |
| LTM Mar 2026 | CA$8.17M CAD | -225.0% | — | 2.6% | |
| FY2025 | A$2.52M AUD | -518.5% | +3.8% | 49.9% | |
| LTM Mar 2026 | $1.14M USD | -118.2% | — | 1.4% | |
BIOABioAge Labs, Inc. | LTM Mar 2026 | $348K USD | -3.6% | — | 3.4% |
| LTM Mar 2026 | $92K USD | -82.2% | -22.0% | 0.2% | |
| LTM Mar 2026 | $86K USD | -93.0% | — | 0.2% | |
| LTM Mar 2026 | $0 USD | — | — | — | |
| LTM Mar 2026 | €0 EUR | — | — | 0.0% | |
| Peer median (excluding LFCR) | — | -93.0% | +3.8% | 2.0% | |
Competitors are the stored peer set for LFCR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 May 2021 | FY2022 May 2022 | FY2023 May 2023 | FY2024 May 2024 | FY2025 May 2025 |
|---|---|---|---|---|---|
| Net Income | (32.29M) | (116.72M) | (99.56M) | 12.01M | (38.72M) |
| Depreciation & Amortization | 19.87M | 18.06M | 13.18M | 7.95M | 8.03M |
| Deferred Income Tax | (7.87M) | (6.83M) | 357K | 163K | 0 |
| Stock-Based Compensation | 3.36M | 2.61M | 3.61M | 6.2M | 10.16M |
| Change in Working Capital | 9.76M | (3.1M) | 19.79M | (3.7M) | (4.7M) |
| Accounts Receivables | 5.78M | (6.14M) | 10.82M | (2.39M) | (2.26M) |
| Inventory | (2.82M) | (2.18M) | (14.81M) | 862K | 7.69M |
| Accounts Payables | (5.98M) | 9.34M | 16.04M | (6.68M) | (1.67M) |
| Other Working Capital | 12.79M | (4.13M) | 7.74M | 4.51M | (8.45M) |
| Other Non-Cash Items | 23.65M | 83.38M | 45.19M | (22.38M) | 25.02M |
| Operating Cash Flow | 16.47M | (22.59M) | (17.44M) | 257K | (206K) |
| Capital Expenditures | (25.22M) | (29.94M) | (21.48M) | (18.4M) | (13.42M) |
| Acquisitions (Net) | 0 | 73.5M | 16.67M | 0 | 7M |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 45.1M | 0 | 0 | 0 |
| Other Investing Activities | 12.91M | (8.7M) | 0 | 0 | 0 |
| Investing Cash Flow | (12.31M) | 79.96M | (4.81M) | (18.4M) | (6.42M) |
| Debt Repayment | 7.47M | (55.41M) | 3.12M | 2.17M | (18.56M) |
| Common Stock Issued | 0 | 0 | 4.82M | 0 | 23.85M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (10.89M) | (1.61M) | (6.32M) | 5.34M | 1.13M |
| Financing Cash Flow | (3.42M) | (57.02M) | 39.7M | 7.51M | 6.42M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 742K | 348K | 17.45M | (10.63M) | (197K) |
| Free Cash Flow | (8.75M) | (52.53M) | (38.92M) | (18.14M) | (13.62M) |
Lifecore Biomedical, Inc.
NASDAQ:LFCR
Intrinsic Alpha fair value
Locked
Current Price
$6.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.